Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Medical Drug Prior Auth …
    Ask Trek AI about this page
    Modifiedblue cross blue shield - michiganPolicy N/A

    Medical Drug and Step Therapy Prior Authorization List — Medical benefit drugs requiring prior authorization or step therapy

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    List of medical benefit drugs for Medicare Plus Blue and BCN Advantage members that require prior authorization or have step therapy requirements; intended for providers submitting authorization requests.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedical Drug and Step Therapy Prior Authorization List
    Policy CodePolicy N/A
    Change TypeAuthorization requirements added, removed and date updates
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the Medical and Pharmacy Drug PA Portal or OncoHealth as indicated for each drug and document required step therapy trials.
    SourceLink
    POLICY UPDATE CHANGES

    Authorization requirement effective 6/1/2026: J0598 Cinryze.

    Authorization requirement effective 7/1/2026: J3590 Otarmeni.

    Authorization requirement removed effective 7/1/2025: J7601 Ohtuvayre.

    Authorization requirement effective 7/1/2025: J3590 Imaavy, J3590 Zevaskyn, Q9999 Ustekinumab-aauz, Q5135 Tocilizumab-aazg.

    Authorization requirement effective 8/1/2025: Q5153 Opuviz.

    Authorization requirement effective 8/20/2025: J9382 Bizengri, J9289 Opdivo Qvantig, J9275 Uloxcyt, J1326 Vyloy, J9276 Ziihera.

    Authorization requirement effective 9/3/2025: J9210 Gamifant.

    Code updates effective 7/1/2025: J7172 Hympavzi, Q2058 Auctazyl, Q5098 Imuldosa, Q5099 Steqeyma, Q5100 Yesintek.

    Authorization requirement effective 6/1/2025: J3590 Qfitlia.

    Authorization requirement effective 7/1/2025: Q9998 Selarsdi.

    ~70drug entries in this segment (approx.)
    multipleentries with step therapy requirements
    OncoHealthcommon submission channel marked ✓
    Revised Jun 2026document revision date

    Coverage Criteria and Drug-specific Conditions

    Covered with criteria (examples)

    Coverage is conditional based on prior authorization and, where indicated, fulfillment of step therapy requirements as listed per drug.

    Example - Abatacept (J0129): Approval requires prior authorization AND trial and failure of Inflectra or Avsola AND trial and failure of Steqeyma, Pyzchiva or Wezlana; for members with MAPD prescription drug plans, trial and failure of adalimumab and Orencia SC is also required; trial and failure of Steqeyma/Pyzchiva/Wezlana not required for rheumatoid arthritis; Orencia SC not required for aGVHD.

    Supports step therapy logic as written in table.

    Example - Aflibercept (J0177/J0178): Approval requires prior authorization AND trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar.

    Step therapy applies to specified HCPCS codes.

    Example - Botulinum toxins (J0586/J0587/J0589): Approval requires prior authorization AND trial and failure of Botox and Xeomin (preferred drugs do not require prior authorization). Note: step therapy with Xeomin not required for chronic migraines or urinary conditions.

    Specific exceptions noted in table.

    Example - Denosumab (J0897): For Prolia use preferred denosumab biosimilar Stoboclo; for Xgeva use preferred denosumab biosimilar Osenvelt (preferred does not require prior authorization).

    Specifies preferred biosimilars and differing requirements by indication/trade name.

    IV iron step therapy (J1437, J1439)

    Examples of step therapy coverage logic from the list:

    Ferric derisomaltose / Ferric carboxymaltose step therapy: Member must have trial and failure of at least TWO of the following preferred medications: Ferrlecit, Feraheme, Venofer, or INFeD before approval2 of 4

    Preferred drugs do not require prior authorization; Injectafer prior auth not required when received through a dialysis facility.

    G-CSF biosimilar / pegfilgrastim sequencing

    Examples of filgrastim/pegfilgrastim biosimilar/agent sequencing:

    Filgrastim biosimilar requirement: Use both preferred filgrastim biosimilars Nivestym AND Zarxio before authorizing listed filgrastim productsuse both biosimilars

    Applies to entries J1442 and J1447.

    Pegfilgrastim preference for Rolvedon/Ryzneuta/etc: Use all of the following preferred pegfilgrastim drugs: Fulphila AND Neulasta or Neulasta OnPro before specified pegfilgrastim/pegfilgrastim biosimilar productsuse specified pegfilgrastim agents

    Applies to J1449, Q5120, Q5122, Q5127, Q5130 and related entries.

    Biologic and MS disease-modifying therapy step therapy

    Example biologic sequencing requirements for certain infused biologics:

    Anti-TNF / anti-TNFR / IL agents sequencing: Trial and failure of Inflectra AND Avsola AND one of Steqeyma, Pyzchiva or Wezlana is required before several IV biologics (e.g., Simponi Aria, Tremfya IV, Mirikizumab IV, Skyrizi IV); adalimumab trial may also be required for MAPD members.use listed preferred agents

    Preferred drugs do not require prior authorization in those entries.

    MS therapy sequencing for Ocrevus/Briumvi/Tyruko: Trial and failure of dimethyl fumarate, glatiramer and fingolimod required before Ocrevus; additional listed agents required before Briumvi and Tyruko per entries; note that step therapy does not apply for Ocrevus when used for primary progressive multiple sclerosis.use listed DMTs

    See per-code exceptions for disease-specific rules.

    Skyrizi IV (J2327) step therapy

    Covered when step therapy requirements are met

    Skyrizi IV step therapy: Trial and failure of Inflectra or Avsola AND Steqeyma, Pyzchiva or Wezlana; trial and failure of adalimumab is also required for MAPD members

    Preferred drugs listed do not require prior authorization

    Ocrevus (J2350) step therapy

    Covered when step therapy requirements are met

    Ocrevus step therapy: Trial and failure of dimethyl fumarate, glatiramer and fingolimod. Note: Step therapy does not apply for diagnosis of primary progressive multiple sclerosis.

    Vabysmo and ranibizumab (J2777/J2778) step therapy

    Covered when step therapy requirements are met

    Vabysmo step therapy: Trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar; trial and failure of aflibercept, ranibizumab, or Beovu is also required.
    Lucentis step therapy: Trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar.

    Asthma biologics (J2356, J2357, J2786)

    Covered when specified prior biologic trials have failed

    Tezspire step therapy: For eosinophilic asthma: trial and failure of Fasenra or Nucala AND Dupixent; For allergic asthma: trial and failure of Xolair; For oral steroid dependent asthma: trial and failure of Dupixent.
    Reslizumab step therapy: Trial and failure of Fasenra or Nucala AND Dupixent.

    Evenity (J3111) step therapy for osteoporosis

    Covered when step therapy requirements are met

    High-risk osteoporosis: Trial and failure of oral or IV bisphosphonates AND a denosumab product.

    For very high-risk osteoporosis: trial and failure of zoledronate only or a denosumab product only if zoledronate is contraindicated.

    Biosimilar and preferred product steps (multiple entries)

    Coverage contingent on use/trial of preferred biosimilars or preferred drugs

    Bevacizumab biosimilars (J3590 / Q51xx entries): Use both preferred bevacizumab biosimilars Zirabev and Mvasi where specified before other bevacizumab biosimilars or non-preferred bevacizumab products.

    Preferred biosimilars may not require prior authorization for indicated uses.

    Bimzelx and similar step therapy: Trial and failure of Inflectra or Avsola AND Steqeyma, Pyzchiva or Wezlana; trial/failure of Steqeyma/Pyzchiva/Wezlana not required for ankylosing spondylitis; additional adalimumab trial required for MAPD members.

    Submit via Medical and Pharmacy Drug PA Portal; prior auth effective dates noted per plan.

    Denosumab biosimilar preference: Use preferred denosumab biosimilars (e.g., Stoboclo or Osenvelt) where specified; when preferred product is used prior authorization may not be required.

    Applies across multiple Q51xx/Q5136/Q5157 entries.

    Example: Bimzelx/J3590 initial coverage conditions

    Covered when specified step therapy and submission rules are followed for the item

    Bimzelx (J3590) initial coverage conditions: Trial and failure of Inflectra OR Avsola AND trial and failure of Steqeyma, Pyzchiva OR Wezlana is required; note: trial/failure of Steqeyma, Pyzchiva or Wezlana is NOT required for ankylosing spondylitis; additional trial of adalimumab required for MAPD members.

    Submit via Medical and Pharmacy Drug PA Portal; prior auth effective dates noted per plan.

    HA (viscosupplementation) step therapy

    Hyaluronic acid intra-articular products

    J7320-J7332 group: Trial and failure of all the following preferred hyaluronic acid drugs is required before authorization: Durolane, Euflexxa, Gelsyn-3 AND Supartz FX.

    Preferred drugs don't require authorization; submit via Medical and Pharmacy Drug PA Portal.

    Bevacizumab preferences and exceptions

    Bevacizumab (J9035) coverage nuance

    Bevacizumab biosimilar preference and retinal exception: Use preferred bevacizumab biosimilars Zirabev and Mvasi where specified; prior authorization is not required when Avastin is used for retinal disorders.

    Submit oncology uses via OncoHealth as indicated.

    Specific drug-level conditions

    Docetaxel (J9172, J9174) and Tyvaso (J7686)

    Docetaxel: Trial and failure of Taxotere is required for certain docetaxel products; Taxotere itself does not require authorization.

    Submit via OncoHealth for these docetaxel entries.

    Tyvaso nebulizer: Prior authorization is required for Tyvaso nebulizer (medical benefit); Tyvaso DPI (J3535) is a pharmacy benefit and handled separately.

    Submit via Medical and Pharmacy Drug PA Portal.

    Coverage conditional on step therapy and prior agents

    Coverage for listed drugs is subject to the specific step therapy rules and prior authorization effective dates shown per J-code.

    Docetaxel (J9172, J9174): Trial and failure of Taxotere is required before approval for certain docetaxel products; Taxotere does not require authorization.

    chunk 73

    Gemcitabine intravesical (J9183): For BCG-unresponsive non‑muscle invasive bladder cancer, must try and fail both Adstiladrin AND Keytruda or Keytruda Qlex.

    chunk 75

    Paclitaxel protein‑bound (J9264): For metastatic breast cancer and non‑small cell lung cancer, must first try and fail generic paclitaxel.

    chunk 77

    Irinotecan liposome (J9205): For pancreatic cancer, must first try and fail conventional irinotecan.

    chunk 75

    Pembrolizumab / Nivolumab nasopharyngeal cancer entries: For use in nasopharyngeal cancer, must first try and fail Loqtorzi where specified.

    chunks 78,79,81,82

    Rituximab / Rituxan Hycela (J9311, J9312): Use all of the preferred rituximab biosimilar drugs: Truxima, Riabni and Ruxience; these preferred drugs don't require authorization.

    chunks 84,85

    Efgartigimod / Vyvgart (J9332, J9334): For myasthenia gravis: trial and failure of Truxima, Ruxience or Riabni is required. For CIDP and Vyvgart Hytrulo additional trial/failure of Gammagard or Octagam is required.

    chunk 88

    Trastuzumab biosimilar preference

    Covered when ALL of the following are met

    Trastuzumab biosimilar step: Use both preferred trastuzumab biosimilars Ontruzant AND Trazimera for Herceptin (J9355) and Herceptin Hylecta (J9356)

    Preferred biosimilars don't require authorization in some cases; non-preferred product may require prior authorization

    Pegfilgrastim/Filgrastim step therapy

    Coverage conditioned on prior use of preferred products

    Pegfilgrastim preference: Use all of the following preferred pegfilgrastim drugs: Fulphila AND Neulasta or Neulasta OnPro before certain pegfilgrastim biosimilars (e.g., Q5120, Q5122, Q5127, Q5130, Q5120 entries).

    Preferred agents may not require authorization

    Filgrastim preference: Use both preferred filgrastim biosimilars Nivestym AND Zarxio before Releuko and related filgrastim entries.

    Applies to Q5125 and J1442/J1447 entries

    Ranibizumab/bevacizumab policy

    Ranibizumab requirement: Trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar required for ranibizumab products Byooviz (Q5124) and Cimerli (Q5128)
    Bevacizumab biosimilar preference: Use both preferred bevacizumab biosimilars Zirabev and Mvasi before other bevacizumab biosimilars (Q5126, Q5129)

    Preferred drugs don't require authorization

    Tocilizumab/Tyenne requirements

    Tocilizumab / Tofidence / Tyenne step: Trial and failure of Tyenne AND trial and failure of Inflectra or Avsola required for Tofidence (Q5133) and Tyenne (Q5135); for MAPD members additional trial and failure of adalimumab and Tyenne SC is required with listed clinical exceptions (eg, cytokine release syndrome, COVID-19, giant cell arteritis).

    Infliximab and adalimumab not required for cytokine release syndrome or giant cell arteritis; Tyenne SC not required for cytokine release syndrome/COVID-19.

    Tocilizumab biosimilar (Q5135) step therapy

    Coverage for certain biosimilars is contingent on prior trials of preferred agents as specified below.

    Q5135 Tocilizumab-aazg: Coverage requires ALL of the following: trial and failure of Tyenne AND trial and failure of Inflectra or Avsola; for MAPD members also trial and failure of adalimumab and Tyenne SC (except for cytokine release syndrome and COVID-19; infliximab and adalimumab not required for cytokine release syndrome or giant cell arteritis)

    From chunk 108

    Denosumab biosimilars step therapy

    Coverage for denosumab biosimilars requires use of preferred denosumab biosimilars or trial/failure per entry.

    Denosumab biosimilars (Q5136, Q5157, Q5158, Q5159, Q5161, Q5162): Requirement: use the preferred denosumab biosimilar Stoboclo OR Osenvelt as specified per product; when the preferred drug is used, prior authorization may not be required; otherwise prior authorization effective dates apply.

    From chunks 108,116,118,119

    Aflibercept step therapy

    Aflibercept biosimilars and related agents have step therapy requiring prior trial/failure of bevacizumab or its biosimilars.

    Aflibercept biosimilars (Q5147, Q5149, Q5150, Q5153, Q5155): Coverage requires trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar before approving the aflibercept biosimilar.

    From chunks 110,111,114

    Trastuzumab biosimilar requirement

    Trastuzumab biosimilars preference

    Trastuzumab-strf (Q5146): Requirement: use preferred trastuzumab biosimilars Ontruzant AND Trazimera; preferred drugs don't require prior authorization.

    From chunk 110

    Ustekinumab IV step therapy

    Ustekinumab IV biosimilars require trial and failure of preferred ustekinumab products.

    Ustekinumab IV biosimilars (Q9997, Q9998, Q9999): Coverage requires trial and failure of preferred ustekinumab products Steqeyma, Pyzchiva, and Wezlana; those preferred drugs do not require authorization.

    From chunks 120-121

    Preferred products named in the table are identified as not requiring prior authorization and are the required first-line agents for many step therapy rules. Where a step requirement exists, providers must document trial and failure of the specified preferred drug(s) (for example, trials of Inflectra® or Avsola® and Steqeyma®, Pyzchiva® or Wezlana® for certain IV biologics). Use of the preferred product as listed generally means no PA is required; requests for non-preferred or innovator products will require prior authorization and documentation that the preferred option(s) were tried and were ineffective or not tolerated.

    For Injectafer® (J1439), step therapy requires trial and failure of at least two of the preferred IV iron products: Ferrlecit®, Feraheme®, Venofer® or INFeD®. Exception: prior authorization is not required when Injectafer® is administered through a dialysis facility.

    For Simponi Aria® (J1602) and other listed IV biologics that require trials of preferred infliximab biosimilars and ustekinumab alternatives, the table specifically notes that trial and failure of Steqeyma®, Pyzchiva® or Wezlana® is NOT required for rheumatoid arthritis or ankylosing spondylitis.

    Step therapy for Ocrevus® (J2350/J2351) requires trial and failure of listed disease‑modifying therapies (example: dimethyl fumarate, glatiramer and fingolimod) before approval; step therapy does not apply when Ocrevus is used for primary progressive multiple sclerosis.

    Bevacizumab (Avastin®, J9035) has a preferred‑biosimilar sequencing requirement (use both Zirabev® and Mvasi® where specified). Separately, the document states that prior authorization is not required when Avastin is used for retinal disorders.

    The excerpt does not list broad categorical exclusions; rather, coverage limitations are expressed as drug‑specific step therapy requirements or required prior agents. Where clinical or indication exceptions exist, they are noted per line item (for example, disease‑specific exceptions for step therapy).

    The policy notes that Tyenne SC (tocilizumab subcutaneous) is not required as a step prior therapy for specific indications: Tyenne SC is not required for treatment of cytokine release syndrome and COVID‑19. When Tyenne SC is not required, associated step requirements that reference the subcutaneous formulation do not apply for those indications.

    For tocilizumab and certain related entries the list clarifies that infliximab and adalimumab are not required as part of step therapy for some indications. Specifically, infliximab and adalimumab are not required for cytokine release syndrome or giant cell arteritis, so prior trials of those agents are not mandated for those diagnoses.

    HCPCS / Q-code / J-code Listings and Dates

    Covered HCPCS codes (excerpt)HCPCSCovered
    J0129Abatacept (Orencia)
    J0174Lecanemab-irmb (Leqembi)
    J0175Donanemab-azbt (Kisunla)
    J0177Aflibercept (Eylea) HD
    Covered HCPCS codes (continued)HCPCSCovered
    J0178Aflibercept (Eylea)
    J0179Brolucizumab-dbll (Beovu)
    J0180Agalsidase beta (Fabrazyme)
    J0185Aprepitant (Cinvanti)
    J0217Velmanase alfa (Lamzede)
    J0218Olipudase alfa-rpcp (Xenpozyme)
    J0219Avalglucosidase alfa-ngpt (Nexviazyme)
    J0221Alglucosidase alfa (Lumizyme)
    J0222Patisiran (Onpattro)
    J0223Givosiran (Givlaari)
    1–10 of 48
    1/5
    Listed HCPCS J-codes in this segmentHCPCS
    J1325Epoprostenol (Flolan®, Veletri®)
    J1326Zolbetuximab-clzb (Vyloy®)
    J1411Etranacogene dezaparvovec-drlb (Hemgenix®)
    J1413Delandistrogene moxeparvovec-rokl (Elevidys)
    J1427Viltolarsen (Viltepso®)
    J1428Eteplirsen (Exondys 51®)
    J1429Golodirsen (Vyondys 53®)
    J1434Fosaprepitant (Focinvez™)
    J1437Ferric derisomaltose (Monoferric®)
    J1439Ferric carboxymaltose (Injectafer®)
    1–10 of 54
    1/6
    Listed J‑codesHCPCS
    J2323Spinraza (nusinersen) reference appears in list
    J2326Spinraza (nusinersen) listed
    J2327Skyrizi IV (risankizumab-rzaa)
    J2329Briumvi (ublituximab-xiiy)
    J2350Ocrevus (ocrelizumab)
    J2351Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)
    J2356Tezspire (tezepelumab-ekko)
    J2357Xolair (omalizumab)
    J2506Neulasta (pegfilgrastim)
    J2507Krystexxa (pegloticase)
    1–10 of 49
    1/5
    Listed J-/C-codes and descriptionsmixed
    J3590multiple generics/trade names listed under miscellaneous J3590 entries (e.g., Bimzelx/Bimekizumab-bkzx; Exdensur/Depemokimab-ulaa; Enoby/Denosumab-qbde; Xtrenbo/Denosumab-qbde; others)
    C9399Omisirge / Omidubicel-onlv
    J7170Emicizumab-kxwh (Hemlibra)
    J7171ADAMTS13, recombinant-krhn (Adzynma)
    J7172Marstacimab-hncq (Hympavzi)
    J7320Sodium hyaluronate (GenVisc 850)
    J7321Sodium hyaluronate (Visco-3 / Hyalgan)
    J7322High Molecular Weight Viscoelastic Hyaluronan (Hymovis)
    J7324High Molecular Weight Hyaluronan (Orthovisc)
    J7325Hylan G-F 20 (Synvisc, Synvisc-One)
    1–10 of 41
    1/5
    Listed J-codes (sample from chunk 72)HCPCS
    J9063Mirvetuximab soravtansine (Elahere)
    J9119Cemiplimab-rwlc (Libtayo)
    J9144Daratumumab and hyaluronidase-fihj (Darzalex Faspro)
    J9145Daratumumab (Darzalex)
    J9161Denileukin diftitox-cxdl (Lymphir)
    Listed J-codesHCPCS
    J9172Docetaxel (Docivyx)
    J9173Durvalumab (Imfinzi)
    J9174Docetaxel (Beizray)
    J9176Elotuzumab (Empliciti)
    J9177Enfortumab vedotin-ejfv (Padcev)
    J9183Gemcitabine intravesical system (Inlexzo)
    J9184Gemcitabine (Avgemsi)
    J9204Mogamulizumab-kpkc (Poteligeo)
    J9205Irinotecan liposome (Onivyde)
    J9210Emapalumab-lzsg (Gamifant)
    1–10 of 58
    1/6
    J-codes listed (selected)HCPCS
    J9350Lunsumio (Mosunetuzumab-axgb)
    Trastuzumab and related J-codesHCPCS
    J9352Trabectedin (Yondelis)
    J9353Margetuximab-cmkb (Margenza)
    J9354Ado-trastuzumab emtansine (Kadcyla)
    J9355Trastuzumab (Herceptin)
    J9356Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta)
    J9358Fam-trastuzumab-nxki (Enhertu)
    J9359Loncastuximab tesirine-lpyl (Zynlonta)
    Additional J-codesHCPCS
    J9361Efbemalenograstim alfa-vuxw (Ryzneuta)
    J9376Pozelimab-bbfg (Veopoz)
    J9380Teclistamab-cqyv (Tecvayli)
    J9381Teplizumab-mzwv (Tzield)
    J9382Zenocutuzumab-zbco (Bizengri)
    J9601Linvoseltamab-gcpt (Lynozyfic)
    Q20xx–Q20xx CAR-T codesHCPCS
    Q2041Axicabtagene ciloleucel (Yescarta) CAR-T
    Q2042Tisagenlecleucel (Kymriah) CAR-T
    Q2053Brexucabtagene autoleucel (Tecartus) CAR-T
    Q2054Lisocabtagene maraleucel (Breyanzi) CAR-T
    Q2055Idecabtagene vicleucel (Abecma) CAR-T
    Q2056Ciltacabtagene autoleucel (Carvykti) CAR-T
    Q2057Afamitresgene autoleucel (Tecelra)
    Q2058Obecabtagene autoleucel (Aucatzyl)
    Q-codes (biosimilars, pegfilgrastim, bevacizumab, ranibizumab, etc.)HCPCS
    Q5098Ustekinumab-srlf (Imuldosa IV)
    Q5100Ustekinumab-kfce (Yesintek IV)
    Q4074Iloprost (Ventavis)
    Q5101Filgrastim-sndz (Zarxio)
    Q5104Infliximab-abda (Renflexis / unbranded biosimilar)
    Q5107Bevacizumab-awwb (Mvasi)
    Q5108Pegfilgrastim-jmdb (Fulphila)
    Q5110Filgrastim-aafi (Nivestym)
    Q5111Pegfilgrastim-cbqv (Udenyca)
    Q5112Trastuzumab-dttb (Ontruzant)
    1–10 of 28
    1/3
    Listed Q-codes in this document portionHCPCS
    Q5135Tocilizumab-aazg (Unbranded biosimilar)
    Q5136Denosumab-bbdz / Jubbonti / Unbranded biosimilar / Wyost
    Q5146Trastuzumab-strf (Hercessi)
    Q5147Aflibercept-ayyh (Pavblu)
    Q5148Filgrastim-txid (Nypozi)
    Q5151Eculizumab-aagh (Epysqli)
    Q5152Eculizumab-aeeb (Bkemv)
    Q5153Aflibercept-yszy (Opuviz / Unbranded biosimilar)
    Q5154Omalizumab-igec (Omlyclo / Unbranded biosimilar)
    Q5155Aflibercept-jbvf (Yesafili)
    1–10 of 20
    1/2
    Codes with recent additions/removals/authorization changesmixed
    J7601Ohtuvayre
    J7172Hympavzi
    Q2058Auctazyl
    Q5098Imuldosa
    Q5099Steqeyma
    Q5100Yesintek
    J3590multiple branded drugs listed under J3590 (e.g., Imaavy, Zevaskyn, Qfitlia, others)
    Q9999Ustekinumab-aauz (and other Q9999 entries in document)
    Q5135Tocilizumab-aazg
    Q5153Opuviz
    1–10 of 17
    1/2
    Historical and other codes referenced in revisionsmixed
    multipleNumerous HCPCS/CPT codes throughout the revision history (examples include J0870, J9038, J1748, J3490, J3590, J9329, Q5115, J1628, J1299, J3392, J2802, J0870, J1307, J1414, J1552, J3393, J3394, J7171, J9361, etc.)
    inv-48: Prior authorization effective dates
    General notePrior authorization effective dates vary by drug; entries in the table show effective years or specific dates per code.
    Example — J0598 (Cinryze)Prior authorization effective date: 6/1/2026 (Medicare Plus Blue and BCN Advantage).
    Example — many entriesNumerous codes show effective dates across 2017–2024 (see per-line 'Prior authorization requirement effective date').
    Most actionable — what providers must doCheck the 'Prior authorization requirement effective date' column on the specific HCPCS/Q-code line before submitting a PA request — the effective date determines whether prior authorization is required.
    inv-49: Step therapy trial and failure count for certain IV iron products
    RequirementTrial and failure of at least TWO of the following preferred IV iron products: Ferrlecit®, Feraheme®, Venofer® or INFeD®.
    Applies toMonoferric (J1437) and Injectafer (J1439).
    ExceptionInjectafer: prior authorization not required when administered through a dialysis facility (per entry for J1439).
    inv-50: Preferred filgrastim biosimilars required
    Preferred filgrastim biosimilarsUse both Nivestym® AND Zarxio® before authorizing certain filgrastim products (e.g., J1442, J1447; Q5148, Q5125 references).
    Applies toFilgrastim entries (J1442, J1447) and corresponding Q-code biosimilars listed in table entries.
    Submission noteCheck the line item for the required submission portal (OncoHealth vs PA Portal) as indicated for each code.
    inv-51: Very high-risk osteoporosis step
    High-risk osteoporosis stepFor high-risk osteoporosis: trial and failure of oral or IV bisphosphonates AND a denosumab product is required before Evenity (J3111).
    Very high-risk osteoporosis (most actionable)For very high-risk osteoporosis: trial and failure of zoledronate only, OR a denosumab product only if zoledronate is contraindicated.
    SubmissionSubmit PA requests via the Medical and Pharmacy Drug PA Portal as indicated on the J3111 line.
    inv-52: Preferred hyaluronic acid trial list
    Required trial listTrial and failure of Durolane®, Euflexxa®, Gelsyn-3® AND Supartz FX® is required before authorization of listed hyaluronic acid (HA) intra‑articular products (J7320–J7332).
    Preferred drugs statusThese preferred HA drugs do not require prior authorization per the entries; providers must document trials of these preferred agents when requesting non‑preferred HA products.
    SubmissionSubmit PA requests through the Medical and Pharmacy Drug PA Portal as indicated on each J‑code line.
    inv-53: Step therapy requirement examples (ranibizumab/bevacizumab)
    Ranibizumab stepTrial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar is required prior to authorization of ranibizumab biosimilars Byooviz (Q5124) and Cimerli (Q5128).
    Bevacizumab sequencingUse both preferred bevacizumab biosimilars (Zirabev® and Mvasi®) before authorizing other bevacizumab biosimilars as specified (e.g., Q5126, Q5129).
    Submission noteCheck per-line portal: some ranibizumab/bevacizumab entries require submission via the Medical & Pharmacy Drug PA Portal (not OncoHealth).
    inv-54: Prior authorization effective date (examples)
    General rulePrior authorization effective dates are shown per HCPCS/Q-code line and determine whether PA is required for that product and plan year.
    ExamplesMany codes list effective years (e.g., 2017–2024); specific entries show dates such as J0598 = 6/1/2026 and Q5135 = 7/1/2025.
    Most actionable — provider stepAlways verify the 'Prior authorization requirement effective date' on the drug's line prior to submitting: if the effective date is on or before the current date, PA is required.

    What Providers Must Do / Authorization and Step Therapy Instructions

    Prior Authorization

    Obtain prior authorization for listed drugs

    Prior authorization is required for the medical-benefit drugs listed in this document; the table includes per-code effective dates and submission routing (Medical and Pharmacy Drug PA Portal or OncoHealth) that providers must follow when requesting authorization.

    Prior Authorization

    Prior authorization required per J‑code entry

    Follow the per-line entry requirement: each J-code shown in the table has a prior authorization requirement and effective date; submit authorization requests using the portal indicated for that J-code.

    Prior Authorization

    Confirm code-level PA and document step therapy per J‑code

    For each J-code with a step or prior-authorization column, document the required step-therapy trials and request prior authorization using the submission channel noted for that specific J-code.

    Prior Authorization

    J3590 items require PA and specified submission

    When billing under J3590 (miscellaneous HCPCS), include the required prior-authorization submission and follow the per-product step therapy rules and effective dates shown in the J3590 entries.

    Documentation Required

    Use OncoHealth for oncology J‑code authorizations when indicated

    Submit prior authorization requests for oncology J-codes through OncoHealth when the line item indicates OncoHealth; otherwise use the Medical and Pharmacy Drug PA Portal as shown.

    Documentation Required

    Submit PA requests via PA Portal or OncoHealth as indicated

    Many J-codes listed require prior authorization and show the Medical and Pharmacy Drug PA Portal (✓) as the primary submission route; follow the portal indicated on each line.

    Prior Authorization

    Follow PA requirements per HCPCS entry

    The table shows per-HCPCS prior authorization requirements and effective dates; providers must request authorization using the portal identified for each HCPCS entry (Medical & Pharmacy Drug PA Portal or OncoHealth).

    Prior Authorization

    Prior authorization required for listed Q‑codes

    Q-code entries in the list require prior authorization when shown; follow the per-product step therapy rules and submit requests via the Medical and Pharmacy Drug PA Portal or OncoHealth as indicated.

    Documentation Required

    Document step therapy trials and failures

    Providers must document required step-therapy trials (trial and failure of specified preferred alternatives) before prior authorization will be approved for many listed drugs.

    • Document dates, agents tried, and reason for failure/intolerance in the PA request.
    Step Therapy

    Step therapy requirements present (general)

    Step therapy rules are present for multiple drugs; follow the per-drug required trials (examples below) before submitting a PA request.

    • J1437/J1439 (IV iron): trial and failure of at least two of Ferrlecit, Feraheme, Venofer or INFeD.
    • J1442/J1447 (filgrastim): trial of Nivestym AND Zarxio.
    • J1449 (pegfilgrastim): trial of Fulphila AND Neulasta or Neulasta OnPro.
    Step Therapy

    Follow per-drug step therapy listed in table

    For specific drugs, the table lists the exact step-therapy agents that must be tried and failed; providers must document those trials in the authorization request.

    • J1437/J1439: two of Ferrlecit, Feraheme, Venofer or INFeD required.
    • J1442/J1447: Nivestym AND Zarxio required.
    Step Therapy

    Comply with J‑code step therapy lists

    Many J‑codes include step therapy specifying which preferred agents must be tried and failed (e.g., trials of Inflectra/Avsola and Steqeyma/Pyzchiva/Wezlana for several IV biologics); include that documentation in the PA submission.

    Documentation Required

    Document trial and failure evidence for step therapy

    Providers must document required trials and failures specified per J‑code; failure to provide this documentation may prevent approval.

    Documentation Required

    Provide clinical rationale and prior-treatment history

    Summaries in the table show required step-therapy trials for many agents; ensure the PA request identifies the prior agents tried and clinical rationale for failure or intolerance.

    Step Therapy

    Step therapy requirements (per J‑code) — examples

    The table includes examples and summaries of step therapy obligations — providers must follow the step rules shown per product (e.g., docetaxel, intravesical gemcitabine, pegfilgrastim sequencing) and submit supporting documentation.

    • J9172/J9174 (docetaxel): trial and failure of Taxotere required.
    • J9183 (gemcitabine intravesical): must try and fail Adstiladrin and Keytruda or Keytruda Qlex.
    Denial Risk

    Document step therapy trials or risk denial

    Providers must document trials and failures of specified agents (step therapy trials) before prior authorization will be approved for many entries; missing documentation risks denial.

    Documentation Required

    Submit PA requests through the portal shown per line item

    For most entries the Medical and Pharmacy Drug PA Portal is the designated submission channel; oncology/supportive-care J-codes list OncoHealth where indicated. Submit via the portal marked on the line item.

    • If OncoHealth is indicated but the diagnosis is non‑oncology, do not send to OncoHealth — call the Pharmacy Clinical Help Desk (per provider guidance).
    Documentation Required

    Use the indicated portal (PA Portal vs OncoHealth)

    When a line item shows a ✓ for the PA Portal, submit the prior authorization through the Medical and Pharmacy Drug PA Portal; when OncoHealth is indicated submit there for oncology/supportive-care items.

    Documentation Required

    Primary submission channel = Medical & Pharmacy Drug PA Portal unless OncoHealth is marked

    Most J‑codes are routed to the Medical and Pharmacy Drug PA Portal; select oncology and certain J‑codes require OncoHealth — check each line and submit via the channel marked.

    Documentation Required

    Include step therapy details and effective dates when submitting

    Authorization requests should be submitted through the Medical and Pharmacy Drug PA Portal for the majority of J-codes; oncology/supportive-care J-codes list OncoHealth. Include step-therapy and effective-date details in submissions.

    Documentation Required

    OncoHealth submission required for indicated oncology entries

    Some entries show OncoHealth (✓) as the submission portal — when OncoHealth is indicated send the authorization request there and include the documented step-therapy trials required for that drug.

    Denial Risk

    Risk of noncoverage without prior authorization

    Failure to obtain required prior authorization for listed drugs will result in lack of plan coverage; obtain authorization before providing the drug to avoid claim denial.

    Note

    Dialysis facility exception for Injectafer (J1439)

    Injectafer (J1439) has a dialysis‑facility exception: prior authorization is not required when administered through a dialysis facility; otherwise the step therapy and PA rules apply as listed.

    Prior Authorization

    Obtain PA for listed J‑codes to avoid denials

    Prior authorization is required for the J‑codes listed in the table (examples include J2327, J2329, J2350); absence of authorization may lead to claim denial.

    Denial Risk

    Adhere to step therapy or risk PA denial

    Step therapy adherence is required for many entries; if the member hasn't tried and failed the specified preferred agents, prior authorization may be denied.

    Billing Rule

    Use and document preferred biosimilars where required

    For products where preferred biosimilars are named (e.g., bevacizumab biosimilars), providers must document use of the preferred biosimilars as required; not using preferred biosimilars may affect authorization.

    Denial Risk

    J9183 requires prior trials of Adstiladrin and Keytruda

    J9183 (gemcitabine intravesical system) requires documented failure of both Adstiladrin and Keytruda (or Keytruda Qlex) for BCG‑unresponsive non‑muscle invasive bladder cancer; failure to document these prior therapies may cause denial.

    Denial Risk

    Docetaxel step therapy requires Taxotere trial/failure

    Docetaxel products (J9172/J9174) require prior trial and failure of Taxotere; if that trial/failure is not documented, authorization may be denied.

    Denial Risk

    Immunotherapy entries require specified prior agent (Loqtorzi) where indicated

    Some immuno‑oncology agents used for nasopharyngeal cancer (e.g., pembrolizumab/nivolumab entries) require prior trial and failure of Loqtorzi; lack of documentation of that prior therapy may result in denial.

    Denial Risk

    Document trials of preferred biosimilars (rituximab/efgartigimod) before non‑preferred

    Preferred biosimilar sequencing is required for certain entries (e.g., efgartigimod/Vyvgart and rituximab hyaluronidase entries); providers must document trials/failures of the listed preferred biosimilars to avoid denial.

    Denial Risk

    Trastuzumab entries require preferred biosimilar trials

    Trastuzumab products (J9355/J9356 and related Q51xx entries) require use of the preferred trastuzumab biosimilars Ontruzant and Trazimera; failure to document the required trial may lead to prior‑authorization denial.

    Denial Risk

    Failure to document required trials risks denial

    If providers do not document trial and failure of the specified preferred therapies (for example Q5135 requires Tyenne AND Inflectra or Avsola trials; Q5136/Q5157 require preferred denosumab biosimilar use), the PA request may be denied.

    Prior Authorization

    Obtain PA for newly added codes by effective date

    Newly added codes listed in the revision history have effective authorization dates — providers must obtain prior authorization for these codes on or after the stated effective dates to avoid claim denials.

    • Examples: J3590 Imaavy (effective 7/1/2025), Q5153 Opuviz (effective 8/1/2025), J9210 Gamifant (effective 9/3/2025).
    Note
    Note
    Note
    Note

    Initial Therapy / Start-of-Care Criteria

    Initial therapy examples

    Examples of initial step therapy rules from the list:

    Abatacept initial requirement: Trial and failure of Inflectra or Avsola AND trial and failure of Steqeyma, Pyzchiva or Wezlana; additional requirements for MAPD members (adalimumab and Orencia SC).

    From J0129 entry.

    Benlysta (J0490): Trial and failure of subcutaneous Benlysta required before IV formulation as indicated in table.

    From J0490 entry.

    Initial therapy step rules (examples)

    Initial coverage requires trial/failure of preferred agents where specified.

    Ustekinumab IV (Starjemza) initial: Trial and failure of the following preferred ustekinumab drugs: Steqeyma, Pyzchiva and Wezlana are required before authorization; these preferred drugs don't require authorization.

    Submit via Medical and Pharmacy Drug PA Portal; effective date noted per entry.

    Hyaluronic acid products (J7320-J7332): Trial and failure of Durolane, Euflexxa, Gelsyn-3 AND Supartz FX required before authorizing listed HA products.

    Preferred drugs don't require authorization.

    Initial therapy preferences

    Initial therapy preference: Preferred biosimilars and preferred agents should be used first (examples include preferred bevacizumab, pegfilgrastim, filgrastim, trastuzumab biosimilars); failure of preferred agents is required before non-preferred product authorization.

    Failure of preferred agents required before non-preferred product authorization.

    Initial therapy requirements

    Initial therapy for many biosimilars: Initial coverage decisions require trial/failure of listed preferred agents per product; preferred agents are specified and may not require prior authorization.

    From chunks 108 and 110

    Continuation / Renewal Criteria

    Continuation

    Continuation note: Preferred biosimilars referenced in the list do not require authorization for ongoing therapy when the member remains on a preferred product; continuation when using preferred agents is therefore permitted.

    From chunk 93

    Continuation therapy notes

    Continuation for preferred agents: Preferred products (e.g., Steqeyma, Pyzchiva, Wezlana) do not require authorization so continuation when using preferred agents is implied as permitted.

    From chunk 120

    Step Therapy Table and Requirements

    General ruleProvider must document
    Member must trial and fail specified preferred agents listed for the HCPCS/J-code before the plan will authorize the requested non-preferred drug.Documentation of prior trials, dates, and reason for failure or intolerance must be included with the prior authorization request.
    Preferred products named in the table typically do not require prior authorization and must be used first as step therapy when specified.If preferred biosimilars or agents were used, include product name, administration dates, and clinical response to substantiate trial/failure.
    Step therapy is a required condition of coverage for many listed J-/Q-/C-codes; requirements are shown per HCPCS entry in the table.Provider must submit supporting medical records demonstrating failure, intolerance, or contraindication to required prior therapies.
    HCPCSStep therapy requirement
    J1437 (Ferric derisomaltose, Monoferric)Trial and failure of at least TWO of: Ferrlecit®, Feraheme®, Venofer® or INFeD® before approval.
    J1439 (Ferric carboxymaltose, Injectafer)Trial and failure of at least TWO of: Ferrlecit®, Feraheme®, Venofer® or INFeD®; prior authorization not required when administered through a dialysis facility.
    HCPCSStep therapy requirement
    J1442 (Filgrastim, Neupogen)Use both preferred filgrastim biosimilars Nivestym® AND Zarxio® prior to authorizing the listed filgrastim product.
    J1447 (Tbo-filgrastim, Granix)Use both preferred filgrastim biosimilars Nivestym® AND Zarxio® prior to authorization.
    HCPCSStep therapy requirement
    J1449 (Eflapegrastim, Rolvedon)Use all of the following preferred pegfilgrastim drugs before approval: Fulphila® AND Neulasta® or Neulasta OnPro.
    HCPCS (examples)Step therapy requirement
    J1602 (Golimumab, Simponi Aria) / J1628 (Guselkumab, Tremfya IV) / J2267 (Mirikizumab IV) / J2327 (Risankizumab IV, Skyrizi IV)Trial and failure of Inflectra® AND Avsola® AND one of Steqeyma®, Pyzchiva® or Wezlana® is required before these IV biologics; preferred drugs do not require prior authorization (additional MAPD adalimumab requirement may apply).
    J1745 (Infliximab / generic) / J1745 (Infliximab biosimilars Q5104)Trial and failure of Inflectra® AND Avsola® required prior to authorization of infliximab products; preferred biosimilars do not require authorization.
    HCPCSStep therapy requirement / exception
    J2327 (Skyrizi IV)Trial and failure of Inflectra® or Avsola® AND Steqeyma®, Pyzchiva® or Wezlana®; MAPD members may also require trial/failure of adalimumab. Preferred drugs do not require prior authorization.
    HCPCS / Q-codeDocumentation required
    (See individual J/Q entries)Providers must document trials and failures of the named preferred drugs specified per HCPCS/Q-code (product name, dates, clinical response, and reason for discontinuation) when step therapy is required.
    When step therapy appliesEvidence required
    Step therapy is required for many products listed (providers must trial preferred alternatives first as shown per HCPCS/Q-code).Attach records showing prior product trials, dosing, dates, and clinical rationale for failure or intolerance; include MAPD-specific requirements when noted.
    HCPCSStep therapy requirement
    J9172 / J9174 (Docetaxel products)Trial and failure of Taxotere® is required prior to authorization of listed docetaxel products; Taxotere does not require authorization.
    HCPCSStep therapy requirement
    J9183 (Gemcitabine intravesical system, Inlexzo)For BCG-unresponsive non‑muscle invasive bladder cancer, must try and fail both Adstiladrin® AND Keytruda® or Keytruda Qlex™ before authorization.
    HCPCSStep therapy requirement
    J9264 (Paclitaxel protein-bound, Abraxane)For metastatic breast cancer and non‑small cell lung cancer, must first try and fail generic paclitaxel prior to authorization.
    HCPCSStep therapy requirement
    J9205 (Irinotecan liposome, Onivyde)For pancreatic cancer, must first try and fail conventional irinotecan prior to approval.
    HCPCSStep therapy requirement (nasopharyngeal cancer)
    J9271 / J9277 (Pembrolizumab / Keytruda / Keytruda Qlex) and J9299 / J9289 (Nivolumab entries)For use in nasopharyngeal cancer, must first try and fail Loqtorzi (toripalimab) where specified before authorization.
    HCPCS examplesBiosimilar-first requirement
    J9256 (Imaavy) / J9311, J9312 (Rituximab Hycela / Rituxan) / J9332–J9334 (Efgartigimod / Vyvgart entries)Trial and failure of listed preferred biosimilars (e.g., Truxima, Ruxience, Riabni) is required before approving the referenced product; preferred biosimilars do not require authorization.
    HCPCS / Q-codeSpecific trial/failure requirements
    J9355 / J9356 (Trastuzumab / Herceptin / Herceptin Hylecta) and Q5146 (Trastuzumab-strf)Use both preferred trastuzumab biosimilars Ontruzant® AND Trazimera® prior to authorizing trastuzumab products; preferred biosimilars may not require prior authorization.
    Q5124 / Q5128 (Ranibizumab Byooviz / Cimerli)Trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar required before authorization.
    Q/HCPCSTocilizumab-related step therapy
    Q5133 / Q5135 (Tofidence / Tyenne / tocilizumab entries)Trial and failure of Tyenne (tocilizumab) AND trial and failure of Inflectra® or Avsola® required for certain tocilizumab entries; MAPD members may also require trial/failure of adalimumab and Tyenne SC. Tyenne SC and infliximab/adalimumab are not required for cytokine release syndrome or COVID‑19 as noted.
    Update summaryNotes
    Step therapy additions/updatesThe document notes additions and updates to step therapy requirements for multiple agents (examples: added step therapy for Keytruda and Opdivo in nasopharyngeal cancer; multiple J3590 and Q-code updates effective on listed dates). Providers should review effective dates per HCPCS/Q-code.

    Site of Care and Submission Routing

    Documentation Required

    Submission routing: PA Portal (general) vs OncoHealth (oncology)

    Use the Medical and Pharmacy Drug PA Portal for most submissions; oncology/supportive care submissions are routed to OncoHealth per the table — follow the portal indicated for each drug.

    Note

    Dialysis‑facility exception for Injectafer

    Injectafer (J1439) prior authorization is not required when administered through a dialysis facility; verify site of care when submitting.

    Note

    Administration settings — infusion center/office/hospital outpatient

    Most therapies are administered in infusion centers, physician offices, or hospital outpatient settings; submit authorizations via the Medical and Pharmacy Drug PA Portal or OncoHealth as specified per line item.

    Note

    Tyvaso: nebulizer (medical) requires PA; DPI is pharmacy benefit

    Tyvaso nebulizer (J7686) is a medical‑benefit product that requires prior authorization; Tyvaso DPI (J3535) is a pharmacy benefit and handled separately.

    Documentation Required

    OncoHealth vs PA Portal indicated per product (site implication)

    Some entries indicate OncoHealth as the submission portal (suggesting oncology/infusion center administration) while others use the Medical and Pharmacy Drug PA Portal; follow the table per product.

    Biosimilar Preferences and Required Trials

    Billing Rule

    Aflibercept requires prior trial/failure of bevacizumab

    Bevacizumab/aflibercept sequencing: aflibercept products require trial and failure of bevacizumab (Avastin) or a bevacizumab biosimilar prior to approval.

    Billing Rule

    Denosumab — use preferred biosimilars (Stoboclo/Osenvelt) where specified

    Denosumab entries (Prolia/Xgeva and biosimilars) specify preferred denosumab biosimilars (Stoboclo for Prolia; Osenvelt for Xgeva); preferred products may not require prior authorization.

    Billing Rule

    Filgrastim/pegfilgrastim preferred biosimilar sequencing required

    Filgrastim/pegfilgrastim sequencing: providers must use preferred filgrastim biosimilars Nivestym AND Zarxio before authorizing listed filgrastim products (J1442/J1447); preferred pegfilgrastim sequencing is required for several Q‑codes.

    Billing Rule

    IV biologics: trial/failure of Inflectra, Avsola and listed ustekinumab products

    Several IV biologics require trial and failure of Inflectra AND Avsola and one of Steqeyma/Pyzchiva/Wezlana before the listed agents; adalimumab may also be required for MAPD members.

    Billing Rule

    Bevacizumab biosimilars (Zirabev, Mvasi) preferred for J3590

    For J3590 entries referencing bevacizumab, use the preferred bevacizumab biosimilars Zirabev and Mvasi as specified for J3590 submissions.

    Billing Rule

    Denosumab preferred biosimilar Stoboclo specified

    Denosumab preferred biosimilar Stoboclo is specified for certain denosumab product entries — when the preferred product is used prior authorization may not be required.

    Billing Rule

    Denosumab preferred biosimilar Osenvelt specified

    Denosumab preferred biosimilar Osenvelt is identified for specified denosumab entries; the preferred product may not require prior authorization.

    Billing Rule

    Preferred bevacizumab biosimilars may not require PA for indicated uses

    Preferred bevacizumab biosimilars (Zirabev, Mvasi) do not require prior authorization for indicated uses; use them before non-preferred bevacizumab products.

    Billing Rule

    Denosumab entries — preferred biosimilars reduce PA need

    Denosumab is listed with multiple trade names; when a preferred denosumab biosimilar is used (Stoboclo or Osenvelt) prior authorization may not be required.

    Billing Rule

    Rituximab biosimilar sequencing required

    Preferred rituximab biosimilars (Truxima, Ruxience, Riabni) must be used prior to brand rituximab products; the preferred biosimilars do not require authorization.

    Billing Rule

    Ontruzant & Trazimera preferred for trastuzumab

    Preferred trastuzumab biosimilars Ontruzant and Trazimera are identified as the required step agents for trastuzumab products (Ontruzant and Trazimera should be used before other trastuzumab products).

    Billing Rule

    Pegfilgrastim preferred‑agent sequencing required

    Pegfilgrastim biologics have preferred sequencing (Fulphila AND Neulasta or Neulasta OnPro) required before certain pegfilgrastim biosimilars; providers must document prior use of these preferred agents.

    Billing Rule

    Zirabev and Mvasi preference for bevacizumab Q‑codes

    Bevacizumab preferred biosimilars Zirabev and Mvasi are required to be used before other bevacizumab biosimilars in select Q-code entries.

    Billing Rule

    Q5136 denosumab entry — Stoboclo preferred

    Q5136 (Denosumab/Jubbonti) requires the preferred denosumab biosimilar Stoboclo where indicated.

    Billing Rule

    Stoboclo or Osenvelt preferred for denosumab biosimilars

    Preferred denosumab biosimilars Stoboclo or Osenvelt are specified across multiple Q-code entries; using the preferred product may obviate prior authorization.

    Billing Rule

    Ontruzant and Trazimera required first for trastuzumab

    Ontruzant and Trazimera are the preferred trastuzumab biosimilars required to be tried prior to non-preferred trastuzumab formulations; preferred agents typically do not require prior authorization.

    Billing Rule

    Ustekinumab IV: trial/failure of preferred products required

    Preferred ustekinumab products (Steqeyma, Pyzchiva, Wezlana) must be tried and failed before coverage of IV ustekinumab biosimilars (Q9997/Q9998/Q9999).

    Background and Scope

    This document is an administrative prior authorization and step therapy list for Medicare Plus Blue and BCN Advantage members covering medical‑benefit drugs. It indicates which HCPCS/Q‑codes require prior authorization, identifies step therapy or preferred‑biosimilar sequencing rules, and shows the submission channel (primarily the Medical and Pharmacy Drug PA Portal or OncoHealth where indicated). The list is intended for providers and includes effective dates and site‑of‑care notes (for example, dialysis facility exceptions).

    Definitions

    inv-93: Prior authorization definition
    DefinitionPrior authorization: approval needed from the plan before the plan will cover the drug.
    PurposeEnsures medication safety and guides appropriate use for selected medical‑benefit drugs listed in this document.
    Provider actionObtain plan approval (PA) before administration or billing for drugs listed with a PA requirement to avoid denial of coverage.
    inv-94: Step therapy definition
    DefinitionStep therapy: a requirement that members try another drug to treat a condition before the plan will cover the requested drug.
    How it's appliedRefer to the 'Step therapy requirement' column for the specific alternative(s) that must be tried and failed before authorization will be granted.
    Provider actionDocument trial and failure (or contraindication/intolerance) of the specified preferred agent(s) when submitting a PA request.
    inv-95: Step therapy (preferred meds) definition
    DefinitionStep therapy (preferred meds): a requirement that the member try and fail specified preferred medications (often biosimilars or alternative agents) before the request for the listed non‑preferred drug will be authorized.
    ExamplesPreferred pegfilgrastim sequence (Fulphila AND Neulasta/Neulasta OnPro) and filgrastim biosimilars (Nivestym AND Zarxio) are required before certain products per the table.
    DocumentationPA requests must include evidence of prior use and failure of the named preferred medications or a documented contraindication/intolerance.
    inv-96: Preferred drugs definition
    DefinitionPreferred drugs: products named in the list (e.g., Inflectra®, Avsola®, Steqeyma®, Pyzchiva®, Wezlana®, etc.) that do not require prior authorization and are listed as required trial options in step therapy.
    ImplicationWhen preferred drugs are used first, prior authorization may not be required; non‑preferred products generally require documentation of trial/failure of preferred options.
    Provider actionUse preferred agents where clinically appropriate to avoid PA requirements and include prior therapy details in PA submissions when step therapy applies.
    inv-97: Retinal disorders exception (Avastin)
    Retinal exceptionBevacizumab (Avastin, J9035): prior authorization is NOT required when used for retinal disorders.
    Other usesFor oncology or non‑retinal uses, bevacizumab entries may require PA and/or preferred biosimilar sequencing per table entries.
    Submission noteOncology uses of bevacizumab are often submitted via OncoHealth when indicated on the line item.
    inv-98: Step therapy (trial & fail) definition
    DefinitionStep therapy (trial & fail): a requirement that the member try and fail specified preferred medications (e.g., listed biosimilars or alternative agents) before the request for the listed non‑preferred drug will be authorized.
    Example — IV ironTrial and failure of at least TWO of Ferrlecit®, Feraheme®, Venofer® or INFeD® required prior to Monoferric (J1437) or Injectafer (J1439).
    Example — filgrastimUse both Nivestym® AND Zarxio® before authorizing listed filgrastim products (J1442, J1447).
    inv-99: Preferred drug definition (contextual)
    Definition (contextual)Preferred drug (contextual): a product identified in the list that does not require prior authorization and must be tried before non‑preferred biosimilars (examples: Tyenne, Inflectra, Avsola, Stoboclo, Osenvelt as listed).
    Practical effectWhen a preferred product is used first, PA may not be required; failure to use preferred product as specified may require additional documentation or lead to denial.
    Provider actionWhen applicable, document use of preferred product(s) or clinical reason for not using them when requesting authorization for non‑preferred agents.

    Revision History and Policy Changes

    2025-07-01authorization_removed

    Authorization requirement removed for J7601 (Ohtuvayre) effective 7/1/2025.

    2026-06-01document_revisionLatest

    Document revised June 2026; includes multiple prior authorization and step therapy updates across listed HCPCS/Q-codes.

    2025-07-01authorization_added

    Authorization requirements added effective 7/1/2025 for J3590 Imaavy, J3590 Zevaskyn, Q9999 Ustekinumab-aauz, and Q5135 Tocilizumab-aazg.

    2025-08-01authorization_added

    Authorization requirement added effective 8/1/2025 for Q5153 Opuviz.

    2025-08-20authorization_added

    Authorization requirements added effective 8/20/2025 for J9382 Bizengri; J9289 Opdivo Qvantig; J9275 Uloxcyt; J1326 Vyloy; and J9276 Ziihera.

    2025-09-03authorization_added

    Authorization requirement added effective 9/3/2025 for J9210 Gamifant.

    2025-06-01authorization_added

    Authorization requirement effective 6/1/2025 added for J3590 Qfitlia.

    2025-07-01authorization_added

    Authorization requirement effective 7/1/2025 added for Q9998 Selarsdi.

    2025-06-01authorization_added

    Authorization requirement effective 6/1/2025 added for J0598 Cinryze (listed in revision history).

    2025-04-01authorization_added

    Authorization requirements effective 5/1/2025 and 6/1/2025 added for multiple Q-codes and J3590 entries (examples: Q5147 Pavblu, Q5149 Enzeevu, Q5150 Ahzantive, Q5151 Epysqli, Q5146 Hercessi, Q5148 Nypozi, J3590 Stoboclo, J3590 Encelto).

    2025-01-06authorization_added

    Authorization requirement effective 1/6/2025 added for certain J3590 entries including Hympavzi and Imuldosa IV noted in earlier revisions.

    Note

    Step therapy updates noted in revision history

    Step therapy updates are documented in the revision history; recent changes include additions of step therapy for Keytruda and Opdivo for nasopharyngeal cancer and other adjustments — review the revision notes for effective dates.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedical Drug and Step Therapy Prior Authorization List
    Policy CodePolicy N/A
    Change TypeAuthorization requirements added, removed and date updates
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the Medical and Pharmacy Drug PA Portal or OncoHealth as indicated for each drug and document required step therapy trials.
    SourceLink
    On This Page
    Coverage Criteria and Drug-specific ConditionsHCPCS / Q-code / J-code Listings and DatesWhat Providers Must Do / Authorization and Step Therapy InstructionsInitial Therapy / Start-of-Care CriteriaContinuation / Renewal CriteriaStep Therapy Table and RequirementsSite of Care and Submission RoutingBiosimilar Preferences and Required TrialsBackground and ScopeDefinitionsRevision History and Policy Changes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.